GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Land And Improvements

Biogen (MEX:BIIB) Land And Improvements : MXN0 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Land And Improvements?

Biogen's land and improvements for the quarter that ended in Mar. 2024 was MXN0 Mil.

Biogen's quarterly land and improvements increased from Sep. 2023 (MXN0 Mil) to Dec. 2023 (MXN3,436 Mil) but then declined from Dec. 2023 (MXN3,436 Mil) to Mar. 2024 (MXN0 Mil).

Biogen's annual land and improvements declined from Dec. 2021 (MXN4,257 Mil) to Dec. 2022 (MXN3,946 Mil) and declined from Dec. 2022 (MXN3,946 Mil) to Dec. 2023 (MXN3,436 Mil).


Biogen Land And Improvements Historical Data

The historical data trend for Biogen's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Land And Improvements Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Land And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,227.37 2,383.06 4,256.66 3,945.99 3,435.59

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 3,435.59 -

Biogen Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


Biogen (MEX:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (MEX:BIIB) Headlines